<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en">
<head><meta http-equiv="Content-Type" content="text/html; charset=">
<title>Handoff Notes and Reminders
</title>
</head>

<body >


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><img height="50" width="200" src="HemOnc%20ExtFR%20TBD%20293295-0100.jpg" 	alt="HemOnc%20ExtFR%20TBD%20293295-0100.jpg" border="0" ></p>
</td>
<td><p><strong>Production Ticket</strong></p>
</td>
</tr>

</table>
<p></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Who?</strong></p>
</td>
<td><p><strong>When?</strong></p>
</td>
<td><p><strong>What?</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>A Haertel</p>
</td>
<td><p>9/30/20</p>
</td>
<td><p>Initiate PT</p>
</td>
</tr>

<tr valign="top">
<td><p>J Quinones</p>
</td>
<td><p>10/30/20</p>
</td>
<td><p>Content updates</p>
</td>
</tr>

<tr valign="top">
<td><p>J Quinones</p>
</td>
<td><p>11/01/20</p>
</td>
<td><p>Light content updates</p>
</td>
</tr>

<tr valign="top">
<td><p>B Betz</p>
</td>
<td><p>11/4/20</p>
</td>
<td><p>LLA questions</p>
</td>
</tr>

<tr valign="top">
<td><p>N Dorkhom</p>
</td>
<td><p>11/5/20</p>
</td>
<td><p>Review LLA Questions</p>
</td>
</tr>

<tr valign="top">
<td><p>J Habib</p>
</td>
<td><p>11/5/20</p>
</td>
<td><p>Outcomes Review</p>
</td>
</tr>

<tr valign="top">
<td><p>J Quinoes</p>
</td>
<td><p>11/5/20</p>
</td>
<td><p>Finalized content</p>
</td>
</tr>

<tr valign="top">
<td><p>B Betz</p>
</td>
<td><p>11/6/20</p>
</td>
<td><p>content check</p>
</td>
</tr>

<tr valign="top">
<td><p>J Quinones</p>
</td>
<td><p>11/6/20</p>
</td>
<td><p>Addressed MED comments</p>
</td>
</tr>

<tr valign="top">
<td><p>A Haertel</p>
</td>
<td><p>11/10/20</p>
</td>
<td><p>Completeness Check</p>
</td>
</tr>

<tr valign="top">
<td><p>S MacLean</p>
</td>
<td><p>11/12/20</p>
</td>
<td><p>copy edit</p>
</td>
</tr>

<tr valign="top">
<td><p>J Quinones</p>
</td>
<td><p>11/16/20</p>
</td>
<td><p>Addressed CE/CAR comments</p>
</td>
</tr>

<tr valign="top">
<td><p>E Nyarko</p>
</td>
<td><p>11/18/20</p>
</td>
<td><p>Expedited CME, ABIM review</p>
</td>
</tr>

<tr valign="top">
<td><p>J Quinones</p>
</td>
<td><p>11/19/20</p>
</td>
<td><p>Prepared for staging production</p>
</td>
</tr>

<tr valign="top">
<td><p>A Simmons</p>
</td>
<td><p>11/20/20</p>
</td>
<td><p>Final Copyedit </p>
</td>
</tr>

</table>
<p>Click <strong>+</strong> to add another table row</p>

<p>&#953; = additional instructions available when you hover cursor over; <strong>Bold text</strong> = questions to be answered</p>
<h1>
<a name="HandoffNotes"></a><a name="Heading55"></a><strong>Handoff Notes and Reminders</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>To Medical Education Directors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Copyeditors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Production/Studio &#953;</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Accreditation/Compliance</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To CPE</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="Heading66"></a><strong>General Information</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Activity SF#(s):</strong></p>
</td>
<td><p>293295-01</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Supporter(s):</strong></p>
</td>
<td><p>Merck Sharp &amp; Dohme International</p>
</td>
<td><p><strong>Partner (s):</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Product type:</strong></p>
</td>
<td><p>First Response</p>
</td>
<td><p><strong>If live event, enter date: </strong> <strong></strong> <strong>If live event, enter time:</strong></p>
</td>
<td><p>(Click to enter date...)  </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>If TH, choose format: </strong></p>
</td>
<td><p>&#9744; Audio summary + full event audio  &#9744; Other, please specify:	</p>
</td>
<td><p><strong>IME program?</strong></p>
</td>
<td><p>&#9746; No   &#9744; Yes</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Outcomes Study included? &#953;</strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes; <strong>measurement focus:</strong> </p>
</td>
<td><p>&#9744; Competence     &#9744; Performance    &#9744;Patient Outcomes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>CME Global program? </strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes</p>
</td>
<td>&nbsp;</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Branding Logos: </strong></p>
</td>
<td><p>&#9744; Medscape  Education</p>
</td>
<td><p>&#9744; Medscape  Education Global</p>
</td>
<td><p>&#9744; Medscape Oncology</p>
</td>
<td><p>&#9744; Medscape  Oncology Global</p>
</td>
<td><p>&#9744; Medscape  Education + theheart.org</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Select one supporter attribution:</strong></p>

<p>&#9746; One Supporter</p>

<p>&#9744; Multi-Support</p>

<p>&#9744; Medscape-supported activity: Developed and funded by Medscape</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Paste badge(s) here</strong>: <img height="65" width="250" src="HemOnc%20ExtFR%20TBD%20293295-0101.jpg" 	alt="HemOnc%20ExtFR%20TBD%20293295-0101.jpg" border="0" ></p>
</td>
</tr>

</table>
<h1>
<a name="Heading100"></a><strong>Course/CME Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Title: &#921;</strong></p>
</td>
<td><p>Expanding the Therapeutic Landscape for Advanced Esophageal and Gastric Cancer: New ICI Treatments</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Teaser: &#953;</strong></p>
</td>
<td><p>Join the faculty as they discuss emerging clinical data, the evolving ICI treatment paradigm, and the role of tumor biomarkers.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Target Audience:</strong></p>
</td>
<td><p>This educational activity is intended for an international audience of non-US hematology/oncology specialists and gastroenterologists. </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Goal Statement: </strong></p>
</td>
<td><p>The goal of this activity is to educate physicians and other healthcare professionals regarding the emerging clinical data on the use of immune checkpoint inhibitors (ICIs) in the treatment of patients with advanced esophageal or gastric cancer (GC).</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Gap: &#953;</strong></p>
</td>
<td><p>Gap 1:&#160;Around 55% of oncologists were not knowledgeable to somewhat knowledgeable&#160;regarding the latest clinical trial data investigating ICI treatment strategies for advanced esophageal and gastric cancer in the first- and second-line setting.</p>

<p>Gap 2:&#160;Around 55% of oncologists were not knowledgeable to somewhat knowledgeable&#160;regarding the role of biomarkers in the management of patients with advanced esophageal and gastric cancer.</p>

<p>Gap 3:&#160;Around 55% of oncologists were not confident to somewhat confident regarding which patients may be eligible for emerging ICI strategies for esophageal and gastric cancer.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Educational Design &#953;</strong></p>
</td>
<td><p>&#9746; Skills/Strategy &#953;</p>
</td>
<td><p>&#9744; Performance &#953;</p>
</td>
<td><p>&#9744; Patient Outcomes &#953;</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>ABMS/ACGME </strong> <strong>Core Competencies &#953;</strong></p>
</td>
<td><p>&#9746; Medical knowledge</p>
</td>
<td><p>&#9744; Patient care and procedural skills</p>
</td>
<td><p>&#9744; Practice-based learning and improvement </p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interpersonal &amp; communication skills</p>
</td>
<td><p>&#9744; Professionalism</p>
</td>
<td><p>&#9744; Systems-based practice</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>IPCE Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Interprofessional Education (IPCE)</p>
</td>
<td><p>&#9744; Roles and Responsibilities                      &#9744; Interprofessional Communication</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td><p>&#9744; Teamwork </p>
</td>
<td><p>&#9744; Values and Ethics</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>CAPE Competencies (Pharmacists)</strong></p>
</td>
<td><p>&#9744; Communication</p>

<p>&#9744; Cultural Sensitivity</p>

<p>&#9744; Educator</p>

<p>&#9744; Health and wellness</p>

<p>&#9744; Innovation and entrepreneurship</p>
</td>
<td><p>&#9744; Interprofessional collaboration</p>

<p>&#9744; Leadership</p>

<p>&#9744; Learner</p>

<p>&#9744; Medication use systems mgmt.</p>

<p>&#9744; Patient advocacy</p>
</td>
<td><p>&#9744; Patient-centered care</p>

<p>&#9744; Population-based care</p>

<p>&#9744; Problem solving</p>

<p>&#9744; Professionalism</p>

<p>&#9744; Self-awareness</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Activity Length &#953;:</strong></p>
</td>
<td><p>46mins</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Credits Available &#953;:</strong></p>

<p>&#9746;<strong> Medscape Joint Accreditation Statement </strong></p>

<p>Direct Provider:</p>

<p>In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>

<p><img height="79" width="124" src="HemOnc%20ExtFR%20TBD%20293295-0102.jpg" 	alt="HemOnc%20ExtFR%20TBD%20293295-0102.jpg" border="0" ></p>
</td>
</tr>

<tr valign="top">
<td><p>&#9746; <strong>ACCME:</strong> 0.75 AMA PRA Category 1&#8482; Credit:</p>

<p>For Physicians</p>

<p>Medscape, LLC designates this enduring material for a maximum of 0.75 <strong><em>AMA PRA Category 1 Credit(s)&#8482;</em></strong>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>ANCC:</strong> (Select credit hours...) contact hours (Select credit hours...) contact hours are in the area of pharmacology)</p>

<p>For Nurses</p>

<p>Awarded (select credit hours...) contact hour(s) of nursing continuing professional development for RNs and APNs; (select contact hours...) contact hours are in the area of pharmacology.</p>

<p>&#9746; <strong>ABIM MOC:  PARS Activity Identifier </strong>201569390</p>
</td>
</tr>

<tr valign="top">
<td><p>Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.</p>

<p>&#9744; <strong>ACPE:</strong> Knowledge-based (Select credit hours...) Contact Hours; ((select CEUs...) CEUs); Application-based (Select credit hours...) Contact Hours ((select CEUs...) CEUs)</p>

<p>(Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>AAPA:</strong> (Select credit hours...) AAPA Category 1 CME credit</p>

<p><img height="77" width="77" src="HemOnc%20ExtFR%20TBD%20293295-0103.jpg" 	alt="HemOnc%20ExtFR%20TBD%20293295-0103.jpg" border="0" ></p>

<p>For Physician Assistants</p>

<p>Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for (Select credit hours...) AAPA Category 1 CME credits. Approval is valid until Expiration Date. PAs should only claim credit commensurate with the extent of their participation.</p>

<p>&#9744; <strong>IPCE:</strong> (Select credit hours...) Interprofessional Continuing Education (IPCE) credit</p>

<p><img height="73" width="102" src="HemOnc%20ExtFR%20TBD%20293295-0104.jpg" 	alt="HemOnc%20ExtFR%20TBD%20293295-0104.jpg" border="0" ></p>

<p>This activity was planned by and for the healthcare team, and learners will receive (Select credit hours...) Interprofessional Continuing Education (IPCE) credit for learning and change.</p>

<p>&#9744; <strong>MIPS:</strong></p>

<p><img height="52" width="126" src="HemOnc%20ExtFR%20TBD%20293295-0105.jpg" 	alt="HemOnc%20ExtFR%20TBD%20293295-0105.jpg" border="0" ></p>

<p>Completion of this accredited CME&#8239;activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).&#160;&#160;</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>CPD:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>OUS Options:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>IME</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>Other:</strong> (Click here to enter...)</p>
</td>
</tr>

</table>
<h1>
<a name="Heading195"></a><strong>Partner Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Partner Statement:</strong></p>

<p><strong>(edit standard statement if needed)</strong></p>
</td>
<td><p>Developed through a partnership between Medscape and enter partner. </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner badge required?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; paste badge here:</p>
</td>
<td><p>  <img height="60" width="200" src="HemOnc%20ExtFR%20TBD%20293295-0106.jpg" 	alt="HemOnc%20ExtFR%20TBD%20293295-0106.jpg" border="0" ></p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Required passing score:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Copyright Statement:</strong></p>
</td>
<td><p>&#9744; &#169; Medscape, LLC</p>
</td>
<td><p>&#9746; &#169; WebMD Global, LLC</p>
</td>
<td><p>&#9744; &#169;  (Add Partner&#8217;s copyright statement...)</p>
</td>
</tr>

</table>
<h1>
<a name="Heading209"></a><strong>Collection Page Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there a collection page?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; <strong>what type?</strong> (Select type...); <strong>provide name and URL:</strong> (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>	If 'Clinical Advances,' which bucket does the content go in?</strong> (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Add to other publications or pages?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; add <strong>URL(s) and bucket name(s) &#953;</strong>: (Click here to enter...)</p>
</td>
</tr>

</table>
<h1>
<a name="Heading219"></a><strong>Product-Specific Information and Add-ons</strong></h1>
<p><em>See Spec Sheet for product-specific details for all products prior to completing this section, especially for a </em><strong><em>multicomponent activity</em> &#953;</strong><em>, </em><strong><em>Slideshow</em> &#953;</strong><em>, and </em><strong><em>Test and Teach</em> &#953;</strong><em>. <strong>A&#160;building block is provided to assist in adding custom components for Directed Learning and </strong></em><strong><em>multicomponent activities</em> &#953;<em> below.</em></strong><em> </em></p>

<p><strong>Component/Chapter: 1 - Introduction</strong></p>

<p><strong>Title:</strong> Expanding the Therapeutic Landscape for Advanced Esophageal and Gastric Cancer: Looking Closely at Upcoming ICI Treatment Strategies</p>

<p><strong>Teaser:</strong> Join Dr Tabernero as he introduces the topics to be discussed in this program.</p>

<p><strong>Author(s) Byline:</strong> Josep Tabernero, MD, PhD</p>

<p><strong>Minutes (for Medscape Micro): </strong></p>

<p><strong>Component/Chapter: 2</strong></p>

<p><strong>Title:</strong> Unmet Needs and Recent Developments in Advanced Esophageal and Gastric Cancer</p>

<p><strong>Teaser:</strong> Join Dr Chau as he discusses the current and evolving treatment paradigm for patients with advanced esophageal and gastric cancer. </p>

<p><strong>Author(s) Byline:</strong> Ian Chau, MD</p>

<p><strong>Minutes (for Medscape Micro): </strong></p>

<p><strong>Component/Chapter: 3</strong></p>

<p><strong>Title:</strong> Emerging Frontline Treatment Strategies With ICIs</p>

<p><strong>Teaser:</strong> Join Dr Tabernero as he discusses new frontline ICI treatment options for the management of patients with esophageal and gastric cancer.</p>

<p><strong>Author(s) Byline:</strong> Josep Tabernero, MD, PhD</p>

<p><strong>Minutes (for Medscape Micro): </strong></p>

<p><strong>Component/Chapter: 4</strong></p>

<p><strong>Title:</strong> Discussing the Role of ICIs After Progression on Chemotherapy</p>

<p><strong>Teaser:</strong> Join Dr Catenacci for a discussion of key clinical data supporting the use of ICIs following progression on chemotherapy in the advanced esophageal and gastric cancer setting.</p>

<p><strong>Author(s) Byline:</strong> Daniel Catenacci, MD</p>

<p><strong>Minutes (for Medscape Micro): </strong></p>

<p><strong>Component/Chapter: 5</strong></p>

<p><strong>Title:</strong> The Role of Biomarkers in the Treatment Paradigm of Esophageal and Gastric Cancer</p>

<p><strong>Teaser:</strong> Join Dr Shah for a discussion of key biomarkers used to guide ICI-based treatment of esophageal and gastric cancer.</p>

<p><strong>Author(s) Byline:</strong> Manish A. Shah, MD</p>

<p><strong>Minutes (for Medscape Micro): </strong></p>

<p><strong>Component/Chapter: 6</strong></p>

<p><strong>Title:</strong> Concluding Remarks</p>

<p><strong>Teaser:</strong> Join Dr Tabernero as he highlights key takeaways from this program.</p>

<p><strong>Author(s) Byline:</strong> Josep Tabernero, MD, PhD</p>

<p><strong>Minutes (for Medscape Micro): </strong></p>

<p>(Select product specific building block, if necessary)</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there an Outcomes study?</strong></p>
</td>
<td><p>Linked Learning Assessment (Medscape)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>If polling questions are included, are they pre/post pairs? </strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a Medscape Discuss or Discuss Lite?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Medscape Discuss</p>
</td>
<td><p>&#9744; Medscape Discuss Lite</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there an associated HCP Perspective?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Does this program have an associated PTL?</strong>	</p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>If a Podcast Series, list name of show:</strong></p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Podcast show Google Play link: </strong></p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Podcast show Apple Podcast link: </strong></p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="Heading286"></a><strong>Learning Objectives and KMI Map</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Upon completion of this activity, </strong> <strong>participants will:</strong></p>
</td>
<td><p><strong>Question type assessing this objective</strong></p>
</td>
<td><p>Question #</p>
</td>
<td><p>Slide #/Chapter #</p>
</td>
<td><p><strong>Learning Needs </strong><em>(*required for any program with an LLA or any CPA posting in a Clinical Advances)</em></p>
</td>
</tr>

<tr valign="top">
<td><p>-	Have increased knowledge regarding the</p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p>&#8226;	Clinical trial data on the use of <a name="_Hlk56066410"></a>immune checkpoint inhibitors (ICIs) as monotherapy or in combination with other agents in advanced esophageal and gastric cancer in the first and second-line setting</p>
</td>
<td><p>Linked Pre-/Post-assessment</p>
</td>
<td><p>1, 2 </p>
</td>
<td><p>Segment 3 slide 3; segment 4 slide 8</p>
</td>
<td><p>N/A</p>
</td>
</tr>

<tr valign="top">
<td><p>&#8226;	Role of biomarkers in the management of patients with advanced esophageal and gastric cancer</p>
</td>
<td><p>CME Posttest</p>
</td>
<td><p>1</p>
</td>
<td><p>Segment 5, Slides 2-9</p>
</td>
<td><p>N/A</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>Linked Pre-/Post-assessment</p>
</td>
<td><p>3</p>
</td>
<td><p>Segment 5, Slides 2-9</p>
</td>
<td><p>Click or tap here to enter text.</p>
</td>
</tr>

<tr valign="top">
<td><p>-	Demonstrate greater confidence in their ability to</p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p>&#8226;	Understand which patients may be eligible for treatment with emerging ICI strategies&#160;</p>
</td>
<td><p>Linked Pre-/Post-assessment</p>
</td>
<td><p>4</p>
</td>
<td><p>Segment 2, Slides 2-17</p>

<p>Segment 5, Slides 2-9</p>
</td>
<td><p>N/A</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<p>Click <strong>+</strong> to add another table row</p>
<h1>
<a name="Heading329"></a><strong>Questions (Evaluations, Assessments, and Posttests)</strong></h1>
<p><em>Place <strong>CME posttest, LLA, and polling questions (pre-assessment/post-assessment pairs, included) i</strong>n this section. Click </em><strong>+</strong><em> to add additional question building blocks as needed. </em></p>

<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question 1:</strong> Which of the following is <strong><u>NOT</u></strong> a tumor biomarker analysis that can be used to guide clinical decisions in determining which patients may benefit from immune checkpoint inhibitor (ICI) therapy in the gastric cancer (GC)/esophageal cancer setting?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#9633;	Tumor mutation burden (TMB) analysis</p>

<p>&#9633;	Combined positive score (CPS) </p>

<p>&#9633;	Tumor positive score (TPS)</p>

<p>&#9633;	Microsatellite instable - low (MSI-L) status</p>

<p>Answer explanation: CPS and TPS are 2 programmed death-ligand 1 (PD-L1) scoring systems that can be used to determine whether patients with GC or esophageal cancer might benefit from ICI therapies such as pembrolizumab. Pembrolizumab may be beneficial among patients with a CPS score of &#8805; 10, but is approved in the GC setting for those with a CPS score of &#8805; 1. In the esophageal cancer setting, TPS scores may be used to indicate nivolumab therapy. Microsatellite instable - high (MSI-H) or TMB status may also be used to determine whether a patient's disease might respond to ICI therapies. Accordingly, the FDA has approved pembrolizumab for patients with tumors that are MSI-H or for tumors that have a TMB of &#8805; 10 Mbp.</p>

<p><a name="_Hlk56066595"></a><a name="_Hlk56066646"></a> </p>
<h1>
<a name="Heading348"></a><strong>LLA Questions</strong></h1>
<p>Question 1</p>

<p><strong>Question type:</strong> Pre/Post Assessment Question Pairs (LLA)</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question:</strong> Which of the following statements best describes the median overall survival (mOS) response observed in the <a name="_Hlk56066659"></a>patients with esophageal squamous cell carcinoma (ESCC) in the KEYNOTE-590 trial?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#9633;	Pembrolizumab showed benefit over placebo only in the programmed death-ligand 1 (PD-L1) combined positive score (CPS) &#8805; 10 subgroup, but not the overall population</p>

<p>&#9633;	Pembrolizumab showed benefit over placebo only in the overall population, but not the PD-L1 CPS &#8805; 10 subgroup</p>

<p>&#9633;	Pembrolizumab showed benefit in both the CPS &#8805; 10 subgroup and the overall population</p>

<p>&#9633;	Pembrolizumab showed no significant benefit over placebo</p>

<p>Answer explanation: The KEYNOTE-590 trial assessed locally advanced unresectable or metastatic ESCC, esophageal adenocarcinoma (EAC), or esophagogastric junction (EGJ) adenocarcinoma patients who were randomized 1:1 to receive either pembrolizumab + chemotherapy or placebo + chemotherapy. The mOS reported in patients with ESCC showed a significant benefit in those patients treated with the pembrolizumab combination (12.6 months [10.2-, 14.3]) vs patients who received the chemotherapy + placebo (9.8 months [8.6, 11.1]). Further, patients who were PD-L1 CPS &#8805; 10 showed a consistent benefit<a name="_Hlk56066690"></a><a name="_Hlk56066696"></a>, with an mOS of 13.9 months (11.1, 17.7) in patients treated with the pembrolizumab combination compared with 8.8 months (7.8, 10.5) in patients treated with the placebo combination.</p>

<p>Question 2</p>

<p><strong>Question type:</strong> Pre/Post Assessment Question Pairs (LLA)</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> Which of the following statements best describes the survival results of the ATTRACTION-3 trial investigating nivolumab vs chemotherapy in the second-line treatment of patients with ESCC?</p>

<p><strong>Question:</strong> </p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#9633;	Nivolumab showed a significant benefit in both overall survival (OS) and progression-free survival (PFS) </p>

<p><a name="_Hlk56066808"></a>&#9633;	Nivolumab showed a significant benefit in OS, but not PFS</p>

<p>&#9633;	Nivolumab showed a significant benefit in PFS, but not OS</p>

<p>&#9633;	There was no benefit observed in nivolumab treatment</p>

<p>Answer explanation: In the ATTRACTION-3 trial, the mOS in patients treated with nivolumab was significantly increased compared to patients treated with chemotherapy (10.9 months [9.2, 13.3] vs 8.4 months [7.2, 9.9], <em>P </em>= .019). There was no PFS benefit observed in patients treated with nivolumab vs chemotherapy (1.7 months [1.5, 2.7] vs 3.4 months [3.0, 4.2]).</p>

<p>Question 3</p>

<p><strong>Question type:</strong> Pre/Post Assessment Question Pairs (LLA)</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question:</strong> Approximately what percentage of patients with gastric cancer (GC) or <a name="_Hlk56066917"></a>GEJ cancer are PD-L1 positive when determining PD-L1 expression by CPS &#8805; 1?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#9633;	20%</p>

<p>&#9633;	40%</p>

<p>&#9633;	60%</p>

<p>&#9633;	80%</p>

<p>Answer explanation: The CPS score determines PD-L1 expression by totaling PD-L1 expression on both tumor and nearby immune cells. CPS has a better negative predictive value than tumor positive score (TPS). In a recent study in patients with gastric and GEJ cancer, PD-L1 expression by CPS &#8805; 1 was observed in 57.6% of the patients.</p>

<p>Question 4 (confidence)</p>

<p><strong>Question must follow question # (optional):</strong></p>

<p><strong>Question:</strong> How confident are you right now in your understanding of which patients are eligible for treatment with emerging immune checkpoint inhibitor (ICI) strategies? (Select ranking from 1 [Not confident] to 5 [Very confident].)</p>

<p><strong>Answer choices:</strong></p>

<p><strong>1 - Not confident</strong></p>

<p><strong>2 - Slightly confident</strong></p>

<p><strong>3 - Moderately confident</strong></p>

<p><strong>4 - Mostly confident</strong></p>

<p><strong>5 - Very confident</strong></p>

<p>Question 5 (demographic)</p>

<p><strong>Question must follow question # (optional):</strong></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than 1 answer?</p>
</td>
</tr>

</table>
<p><strong>Question type:</strong> Demographic</p>

<p><strong>Show question in postassessment or as pre-/post- pair? Postassessment only</strong></p>

<p><strong>Question: </strong>How many patients with GC or GEJ cancer do you treat per month?</p>

<p><strong>Answer Choices:</strong></p>

<p>&#9633;	0</p>

<p>&#9633;	1 to 5</p>

<p>&#9633;	6 to 10</p>

<p>&#9633;	11 to 15</p>

<p>&#9633;	16 to 20</p>

<p>&#9633;	More than 20</p>

<p>Click <strong>+</strong> to add another question</p>

<p><em>Click here to choose a self-efficacy question</em><strong> &#953;</strong></p>

<p>Choose a building block.</p>

<p><em>Click here to choose a demographic question</em></p>

<p>Choose a building block.</p>

<p><em>Place any additional evaluation questions in this section. Add additional question building blocks as needed.</em></p>

<p>(Choose a question type...)</p>

<p>Enter any content that you want to repeat, including other content controls. You can also insert this control around table rows in order to repeat parts of a table.</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>Click <strong>+</strong> to add another question</p>
</td>
</tr>

</table>
<h1>
<a name="Heading431"></a><strong>Content</strong></h1>
<p><strong><em>Select appropriate activity preamble as needed or delete: </em></strong></p>

<p>(Select preamble...)</p>

<p>Introductory Text: </p>

<p><strong><em>OPTIONAL: Select appropriate pre-assessment question preamble:</em></strong></p>

<p><strong>&lt;&lt;level 1&gt;&gt; Educational Impact Challenge</strong></p>

<p>Insert goal statement here.</p>

<p>Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.</p>

<p>&lt;&lt;Insert pre-assessment questions 1-4&gt;&gt;</p>

<p>&#9744;  <strong>COVID Program Disclaimer</strong></p>

<p>Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. In order to facilitate disseminating this educational activity as quickly as possible, the associated slides and transcript will be included 1-2 weeks after the activity posting date.</p>

<p><strong><em>Main Content Instructions:</em></strong></p>

<p><em>Place tables within the text where they should occur. Go to Insert &gt; Quick Parts &gt; Auto Text &gt; Medscape Other Content &gt; Table</em></p>

<p><em>Place instructions for figure placement within the text where each figure should occur. Go to Insert &gt; Quick Parts &gt; Auto Text &gt; Medscape Other Content &gt; Figure</em></p>

<p><em>&lt;&lt;NO TRANSCRIPT&gt;&gt;</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong><em>OPTIONAL: Select appropriate post-assessment question preamble:</em></strong></p>

<p>&lt;&lt;level 1&gt;&gt; Educational Impact Challenge</p>

<p>What did you learn from this activity? Please click on the "Next" button to proceed to a brief survey to see how your knowledge improved after the education. You can also see how your answers compare with those of your peers.</p>

<p>&lt;&lt;Note to Production: Insert page break between preamble and post-assessment questions&gt;&gt; </p>

<p>&lt;&lt;Note to production: Place post-assessment questions 1-5 (selected from the preassessment/intra-activity questions) here&gt;&gt;</p>
</td>
</tr>

</table>
<h1>
<a name="Heading459"></a><strong>Abbreviations</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>1L = first-line</p>

<p>2L = second-line</p>

<p>3L = third-line</p>

<p>4L = fourth-line</p>

<p>5-FU = fluorouracil</p>

<p>ADC = antibody-drug conjugate</p>

<p>Adeno = adenocarcinoma</p>

<p>AE = adverse event</p>

<p>BICR = blinded independent central review</p>

<p>BOR = best overall response</p>

<p>BSC = best supportive care</p>

<p>CapeOX = capecitabine + oxaliplatin</p>

<p>Chemo = chemotherapy</p>

<p>CIN = cervical intraepithelial neoplasia</p>

<p>c-met = mesenchymal epithelial transition factor</p>

<p>CPS = combined positive score</p>

<p>DCF = docetaxel + cisplatin + fluorouracil</p>

<p>DCR = disease control rate</p>

<p>dMMR = deficient mismatch repair</p>

<p>DOR = duration of response</p>

<p>EAC = esophageal adenocarcinoma</p>

<p>EBV = Epstein-Barr virus</p>

<p>ECF = epirubicin + cisplatin + fluorouracil</p>

<p>ECOG = Eastern Cooperative Oncology Group</p>

<p>EGFR = epidermal growth factor receptor</p>

<p>EGJ = esophagogastric junction</p>

<p>ESCC = esophageal squamous cell carcinoma</p>

<p>ESMO = European Society for Medical Oncology</p>

<p>FDA = US Food and Drug Administration</p>

<p>FOLFOX = folinic acid + fluorouracil + oxaliplatin</p>

<p>FP = fluorouracil + cisplatin</p>

<p>G/GEJ = gastric or gastroesophageal junction</p>

<p>GC = gastric cancer</p>

<p>GS = genomically stable</p>

<p>HER2 = human epidermal growth factor receptor 2</p>

<p>ICI = immune checkpoint inhibitor</p>

<p>IO = immune-oncology</p>

<p>IPI3 = 3 mg/kg ipilimumab</p>

<p>Irino = irinotecan</p>

<p>IRRC = immune-related response criteria</p>

<p>IV = intravenous</p>

<p>mGC = metastatic gastric cancer</p>

<p>MMP9 = matrix metallopeptidase 9</p>

<p>mOS = median overall survival</p>

<p>mPFS = median progression-free survival</p>

<p>MSI = microsatellite instable</p>

<p>MSI-H = microsatellite instable - high</p>

<p>MSI-L = microsatellite instable - low</p>

<p>MSS = microsatellite stable</p>

<p>mTOR = mechanistic target of rapamycin</p>

<p>NCCN = National Comprehensive Cancer Network</p>

<p>NIVO = nivolumab&#160;</p>

<p>NIVO1 = 1 mg/kg nivolumab</p>

<p>OG = oesophagogastric</p>

<p>OGJ = oesophagogastric junction </p>

<p>ORR = overall response rate</p>

<p>OS = overall survival</p>

<p>PARP = poly(ADP-ribose) polymerase</p>

<p>PD-1 = programmed cell death protein 1</p>

<p>PD-L1 = programmed death-ligand 1</p>

<p>Pembro = pembrolizumab</p>

<p>PFS = progression-free survival</p>

<p>PS = performance status</p>

<p>R = randomize</p>

<p>RCT = randomized controlled trial</p>

<p>RECIST = response evaluation criteria in solid tumors</p>

<p>RMH = Royal Marsden Hospital prognostic score</p>

<p>SCC = squamous cell carcinoma</p>

<p>SOC = standard of care</p>

<p>Squam = squamous</p>

<p>TMB = tumor mutation burden </p>

<p>TPS = tumor positive score</p>

<p>TRAE = treatment-related adverse event</p>

<p>TTR = Time to recurrence</p>

<p>UC = undifferentiated carcinoma</p>

<p>VEGF = vascular endothelial growth factor</p>
</td>
</tr>

</table>
<h1>
<a name="Heading537"></a><strong>Additional Resources</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><em>Add additional resources below. NOTE: If a <strong>custom downloadable slide kit or custom downloadable PDF</strong> was sold above the </em><strong><em>standard decks</em> &#953;</strong><em> and resources that come with certain activities, it should be noted in the </em><a href="HemOnc%20ExtFR%20TBD%20293295-01.html#HandoffNotes">HANDOFF NOTES AND REMINDERS</a><em> section above (include the custom label for document as well). <strong>Do not indicate here.</strong></em></p>
</td>
</tr>

</table>
<h1>
<a name="Heading540"></a><strong>Related Links</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><em>List 3 to 5 related links to </em><strong><em>content</em> &#953;</strong><em> on medscape.org and the titles of the activities to be added to this activity.</em></p>

<p>Is There a Relationship Between <em>H Pylori</em> and Gastric Cancer? </p>

<p><a href="https://www.medscape.org/viewarticle/926006">https://www.medscape.org/viewarticle/926006</a> </p>

<p>Emerging HER2-Directed Therapies for Gastric and Colorectal Cancer: Expert Insights and Perspectives</p>

<p><a href="https://www.medscape.org/viewarticle/935536">https://www.medscape.org/viewarticle/935536</a> </p>

<p>GI Cancer: Key Drug Interactions to Avoid</p>

<p><a href="https://www.medscape.org/viewarticle/935503">https://www.medscape.org/viewarticle/935503</a> </p>
</td>
</tr>

</table>
<h1>
<a name="Heading550"></a><strong>Disclosures</strong></h1>
<h2>
<a name="Heading551"></a><strong>Faculty Information and Disclosure Statements</strong></h2>
<p><strong><em>Reminder: Complete the COI statements in the Work Front Custom Form prior to sending this document to CME Review</em></strong></p>

<p><strong><em>List in order as to appear on the site; include "host," "moderator," "panelists," or other type of faculty designation when applicable</em></strong></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Faculty/Author(s) Byline(s): &#953;</strong></p>
</td>
<td><p>Josep Tabernero, MD, PhD; Daniel Catenacci, MD; Ian Chau, MD; Manish A. Shah, MD</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9746; Faculty affiliations are confirmed to be accurate</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Josep Tabernero, MD, PhD</strong></p>

<p>Head</p>

<p>Medical Oncology Department</p>

<p>Vall D'Hebron University Hospital</p>

<p>Barcelona, Spain</p>

<p>Disclosure: Josep Tabernero, MD, PhD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Eli Lilly; Foundation Medicine; Genentech; HaliodDX SAS; Menarini; Merck Serono; Merus; MSD; Novartis; Peptomyc; Pfizer; Roche; Roche Diagnostitcs; Sanofi; Seattle Genetics; Servier; Taiho Pharmaceutical</p>

<p>&#9744; Served as a speaker or a member of a speakers bureau for: (Click here to enter...)</p>

<p>&#9744; Received grants for clinical research from: (Click here to enter...)</p>

<p>&#9744; Owns stock, stock options, or bonds from: (Click here to enter...)</p>

<p>&#9744; Other: (Click here to enter...)</p>

<p><strong>Daniel Catenacci, MD</strong></p>

<p>Associate Professor of Medicine </p>

<p>Director</p>

<p>Gastrointestinal Oncology Program</p>

<p>University of Chicago</p>

<p>Chicago, Illinois, United States</p>

<p>Disclosure: Daniel Catenacci, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Astellas; BMS; Daichii Sankyo; Eli Lilly; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone; Guardant Health; Merck; Pieris; Seattle Genetics; Taiho; Tempus; ZymeWorks </p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: BMS; Eli Lilly; Genentech/Roche; Guardant Health; Merck; Tempus</p>

<p>&#9744; Received grants for clinical research from: (Click here to enter...)</p>

<p>&#9744; Owns stock, stock options, or bonds from: (Click here to enter...)</p>

<p>&#9744; Other: (Click here to enter...)</p>

<p><strong>Ian Chau, MD</strong></p>

<p>Consultant Medical Oncologist</p>

<p>The Royal Marsden Hospital</p>

<p>London &amp; Surrey, United Kingdom</p>

<p>Disclosure: Ian Chau, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: AstraZeneca; Bayer; Boehringer Ingelheim; BMS; Eli Lilly; Five Prime Therapeutics; Merck-Serono; Oncology International; Pierre Fabre; Roche </p>

<p>&#9744; Served as a speaker or a member of a speakers bureau for: (Click here to enter...)</p>

<p>&#9746; Received grants for clinical research from: Eli Lilly; Janssen-Cilag; Sanofi Oncology</p>

<p>&#9744; Owns stock, stock options, or bonds from: (Click here to enter...)</p>

<p>&#9744; Other: Honorarium from Eli Lilly</p>

<p><strong>Manish A. Shah, MD</strong></p>

<p>Chief, Solid Tumor Oncology Service Director</p>

<p>Co-Director, Center for Advanced Digestive Care</p>

<p>Bartlett Family Professor of Gastrointestinal Oncology</p>

<p>Weill Cornell Medicine/New York Presbyterian Hospital</p>

<p>New York, New York, United States</p>

<p>Disclosure: Manish A. Shah, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9744; Served as an advisor or consultant for: (Click here to enter...)</p>

<p>&#9744; Served as a speaker or a member of a speakers bureau for: (Click here to enter...)</p>

<p>&#9746; Received grants for clinical research from: BMS; Merck; Oncolys Pharma </p>

<p>&#9744; Owns stock, stock options, or bonds from: (Click here to enter...)</p>

<p>&#9744; Other: (Click here to enter...)</p>

<p>Special Instructions for <strong>EBAC</strong> programs or faculty from <strong>Johns Hopkins University or Emory University/Healthcare</strong>: Special disclosure language or disclaimer statements must be used (EBAC: place BEFORE authors; JHU and Emory place statement AFTER faculty affiliation and BEFORE disclosure information):</p>

<p>(Select disclosure statement...)</p>
</td>
</tr>

</table>
<h2>
<a name="Heading604"></a><strong>MED/Editor/Writer Information and Disclosure Statements</strong></h2>
<p><strong><em>List in order as to appear on the site.</em></strong><em> Click </em><strong>+</strong><em> to add more</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Briana Betz, PhD</strong></p>

<p>Medical Education Director, Medscape, LLC</p>

<p>Disclosure: Briana Betz, PhD, has disclosed no relevant financial relationships.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Jason Luis Quinones, PhD</strong></p>

<p>Scientific Content Manager, Medscape, LLC</p>

<p>Disclosure: Jason Luis Quinones, PhD, has disclosed no relevant financial relationships.</p>
</td>
</tr>

</table>
<h2>
<a name="Heading612"></a><strong>Additional Planners/Reviewers Information and Disclosure Statements</strong></h2>
<p><strong><em>Select the appropriate CME reviewer involved in the project using the building block below.</em></strong><em> Click </em><strong>+</strong><em> to add more reviewers</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><a name="_Hlk17899334"></a><strong>CME Reviewer &#953;</strong></p>

<p>Esther Nyarko, PharmD</p>

<p>Associate Director, Accreditation and Compliance, Medscape, LLC</p>

<p>Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.</p>

<p>&#9746; Medscape, LLC staff have disclosed that they have no relevant financial relationships.</p>

<p><strong>&#9746; Peer Reviewer</strong></p>

<p>This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.</p>

<p>(Click here to enter...)</p>
</td>
</tr>

</table>
<h1>
<a name="Heading625"></a><strong>References</strong></h1>
<p>Ajani JA, Kato K, Doki Y, et al. CheckMate 648: a randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma. <em>J Clin Oncol</em>. 2018;36:TPS193.</p>

<p>Bang Y-J, Xu RH, Chin K, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <em>Lancet Oncol</em>. 2017;18:1637-1651.</p>

<p>Bang Y-J, Ya&ntilde;ez Ruiz E, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. <em>Ann Oncol</em>. 2018;29:2052-2060.</p>

<p>Boku N, Ryu MH, Oh D, et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Presented at: European Society for Medical Oncology Virtual Congress; September 19-21, 2020; Madrid, Spain. Abstract LBA7. <a href="https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-previously-untreated-advanced-or-recurrent-gastric-gastroesophageal-junction">https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-previously-untreated-advanced-or-recurrent-gastric-gastroesophageal-junction</a> </p>

<p>ClinicalTrials.gov. A study to evaluate efficacy in subjects with esophageal cancer treated with nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin (CheckMate 648). Accessed November 12, 2020. <a href="https://clinicaltrials.gov/ct2/show/NCT03143153">https://clinicaltrials.gov/ct2/show/NCT03143153</a> </p>

<p>ClinicalTrials.gov. Pembrolizumab/placebo plus trastuzumab plus chemotherapy in human epidermal growth factor receptor 2 positive (HER2+) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (MK-3475-811/KEYNOTE-811). Accessed November 12, 2020. <a href="https://clinicaltrials.gov/ct2/show/NCT03615326">https://clinicaltrials.gov/ct2/show/NCT03615326</a></p>

<p>Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. <em>N Engl J Med</em>. 2008;358:36-46.</p>

<p>Davidson M, Cafferkey C, Goode EF, et al. Survival in advanced esophagogastric adenocarcinoma improves with use of multiple lines of therapy: results from an analysis of more than 500 patients. <em>Clin Colorectal Cancer</em>. 2018;17:223-230.</p>

<p>Davidson M, Chau I, Cunningham D, et al. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. <em>World J Gastrointest Oncol</em>. 2017;9:333-340.</p>

<p>Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <em>Lancet Oncol. </em>2014;15:78-86.</p>

<p>Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. <em>JAMA Oncol</em>. 2018;4:e180013.</p>

<p>Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <em>Lancet</em>. 2014;383:31-39.</p>

<p>International Agency for Research on Cancer. GLOBOCAN 2018 cancer data. Accessed October 28, 2020. <a href="https://gco.iarc.fr/today/online-analysis-pie?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0&population_group_globocan_id=">https://gco.iarc.fr/today/online-analysis-pie?v=2018&amp;mode=cancer&amp;mode_population=continents&amp;population=900&amp;populations=900&amp;key=total&amp;sex=0&amp;cancer=39&amp;type=0&amp;statistic=5&amp;prevalence=0&amp;population_group=0&amp;ages_group%5B%5D=0&amp;ages_group%5B%5D=17&amp;nb_items=7&amp;group_cancer=1&amp;include_nmsc=1&amp;include_nmsc_other=1&amp;half_pie=0&amp;donut=0&amp;population_group_globocan_id=</a>. </p>

<p>Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. <em>J Clin Oncol. </em>2012;30:1513-1518.</p>

<p>Kang Y-K, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <em>Lancet</em>. 2017;390:2461-2471.</p>

<p>Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <em>Lancet Oncol</em>. 2019;20:1506-1517.</p>

<p>Kato K, Sun J, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Presented at: European Society for Medical Oncology Virtual Congress; September 19-21, 2020; Madrid, Spain. Abstract LBA8. <a href="https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-plus-chemotherapy-versus-chemotherapy-as-first-line-therapy-in-patients-with-advanced-esophageal-cancer-the-phase-3-keynote-590-study">https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/pembrolizumab-plus-chemotherapy-versus-chemotherapy-as-first-line-therapy-in-patients-with-advanced-esophageal-cancer-the-phase-3-keynote-590-study</a> </p>

<p>Kim J, Kim B, Kang SY, et al. Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer. <em>Front Oncol</em>. 2020;10:314.</p>

<p>Kim S-B, Doi T, Kato K, et al. KEYNOTE-181: pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy. <em>Ann Oncol</em>. 2019;30:IX42-IX43.</p>

<p>Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. <em>Arch Pathol Lab Med</em>. 2019;143:330-337.</p>

<p>Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em>. 2016;27:v50-v57.</p>

<p>Lorenzen S, Knorrenschild JR, Pauligk C, et al. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). <em>Int J Cancer</em>. 2020. doi: 10.1002/ijc.33025. [Epub ahead of print] </p>

<p>Moehler M, Ryu M-H, Dvorkin M, et al. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <em>Future Oncol</em>. 2019;15:567-577.</p>

<p>Moehler M, Shitara K, Garrido M, et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemotherapy as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Presented at: European Society for Medical Oncology Virtual Congress; September 19-21, 2020; Madrid, Spain. Abstract LBA6. <a href="https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-nivo-plus-chemotherapy-chemo-versus-chemo-as-first-line-1l-treatment-for-advanced-gastric-cancer-gastroesophageal-junction-cancer">https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/nivolumab-nivo-plus-chemotherapy-chemo-versus-chemo-as-first-line-1l-treatment-for-advanced-gastric-cancer-gastroesophageal-junction-cancer</a> </p>

<p>National Cancer Institute (NCI) dictionary. Immune checkpoint inhibitor. Accessed November 19, 2020. <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor">https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor</a> </p>

<p>National Comprehensive Cancer Network (NCCN). NCCN Guidelines&reg;. Esophageal and esophagogastric junction cancers. Version 4.2020. Accessed October 20, 2020. <a href="https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf">https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf</a> </p>

<p>National Comprehensive Cancer Network (NCCN). NCCN Guidelines&reg;. Gastric cancer. Version 3.2020. Accessed November , 2020. <a href="https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf">https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf</a></p>

<p>Shah MA, Shitara K, Lordick F, et al. The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. <em>J Clin Oncol</em>. 2018;36:4010.</p>

<p>Shitara K, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <em>Lancet Oncol</em>. 2018;19:1437-1448.</p>

<p>Shitara K, &Ouml;zg&uuml;ro&#287;lu M, Bang Y-J, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <em>Lancet</em>. 2018;392:123-133.</p>

<p>Shitara K, Van Cutsem E, Bang Y-J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. <em>JAMA Oncol</em>. 2020;6:1571-1580.</p>

<p>Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em>. 2016;27:v38-v49.</p>

<p>The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. <em>Nature</em>. 2017;541:169-175.</p>

<p>Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <em>Eur J Cancer. </em>2011;47:2306-2314.</p>

<p>Thuss-Patience PC, Shah MS, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <em>Lancet Oncol</em>. 2017;18:640-653.</p>

<p>Wainberg ZA, Fuchs CS, Tabernero J, et al. Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS &#8805;10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies. <em>J Clin Oncol. </em>2020;38: Abstract 427.</p>

<p>Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <em>Lancet Oncol</em>. 2014;15:1224-1235.</p>

<p>Xu J, Bai Y, Xu N, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma. <em>Clin Cancer Res</em>. 2020;26:4542-4550.</p>


</body>

</html>
